Pulse pressure and diabetes treatments Blood pressure and pulse pressure difference among glucose lowering modality groups in type 2 diabetes

被引:7
作者
Alemi, Hamid [1 ]
Khaloo, Pegah [1 ]
Mansournia, Mohammad Ali [2 ]
Rabizadeh, Soghra [1 ]
Salehi, Salome Sadat [1 ]
Mirmiranpour, Hossein [1 ]
Meftah, Neda [1 ]
Esteghamati, Alireza [1 ]
Nakhjavani, Manouchehr [1 ]
机构
[1] Vali Asr Hosp, Sch Med, EMRC, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran
关键词
cardiovascular safety; glibenclamide; insulin; metformin; pulse pressure; systolic and diastolic blood pressure; type 2 diabetes mellitus; CORONARY-HEART-DISEASE; CARDIOVASCULAR SAFETY; ARTERIAL STIFFNESS; GLYCEMIC CONTROL; NONDIABETIC PATIENTS; INSULIN-RESISTANCE; METFORMIN; RISK; MORTALITY; SULFONYLUREAS;
D O I
10.1097/MD.0000000000009791
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is associated with higher pulse pressure. In this study, we assessed and compared effects of classic diabetes treatments on pulse pressure (PP), systolic blood pressure (SBP), and diastolic blood pressure (DBP) in patients with type 2 diabetes. In a retrospective cohort study, 718 non-hypertensive patients with type 2 diabetes were selected and divided into 4 groups including metformin, insulin, glibenclamide+metformin, and metformin+insulin. They were followed for 4 consecutive visits lasting about 45.5 months. Effects of drug regimens on pulse and blood pressure over time were assessed separately and compared in regression models with generalized estimating equation method and were adjusted for age, duration of diabetes, sex, smoking, and body mass index (BMI). Studied groups had no significant change in PP, SBP, and DBP over time. No significant difference in PP and DBP among studied groups was observed (PP: P=0.090; DBP: P=0.063). Pairwise comparisons of PP, SBP, and DBP showed no statistically significant contrast between any 2 studied groups. Interactions of time and treatment were not different among groups. Our results demonstrate patients using metformin got higher PP and SBP over time. Averagely, pulse and blood pressure among groups were not different. Trends of variation in pulse and blood pressure were not different among studied diabetes treatments.
引用
收藏
页数:7
相关论文
共 56 条
[1]  
Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc13-S067, 10.2337/dc14-S081, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc13-S011, 10.2337/dc11-S011, 10.2337/dc10-S062, 10.2337/dc12-s011, 10.2337/dc12-s064]
[2]   Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines [J].
Bird, Steven T. ;
Hartzema, Abraham G. ;
Etminan, Mahyar ;
Brophy, James M. ;
Delaney, Joseph. A. C. .
GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (04) :365-369
[3]   Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management Reflections From a Diabetes Care Editors' Expert Forum [J].
Cefalu, William T. ;
Buse, John B. ;
Del Prato, Stefano ;
Home, Philip D. ;
LeRoith, Derek ;
Nauck, Michael A. ;
Raz, Itamar ;
Rosenstock, Julio ;
Riddle, Matthew C. .
DIABETES CARE, 2014, 37 (09) :2647-2659
[4]  
Charles MA, 2000, DIABETES-METAB RES, V16, P2, DOI 10.1002/(SICI)1520-7560(200001/02)16:1<2::AID-DMRR75>3.0.CO
[5]  
2-G
[6]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[7]   Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus [J].
Cockcroft, JR ;
Wilkinson, IB ;
Evans, M ;
McEwan, P ;
Peters, JR ;
Davies, S ;
Scanlon, MF ;
Currie, CJ .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (11) :1463-1467
[8]   PULSATILE VERSUS STEADY COMPONENT OF BLOOD-PRESSURE - A CROSS-SECTIONAL ANALYSIS AND A PROSPECTIVE ANALYSIS ON CARDIOVASCULAR MORTALITY [J].
DARNE, B ;
GIRERD, X ;
SAFAR, M ;
CAMBIEN, F ;
GUIZE, L .
HYPERTENSION, 1989, 13 (04) :392-400
[9]   Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register [J].
Ekstrom, Nils ;
Svensson, Ann-Marie ;
Miftaraj, Mervete ;
Franzen, Stefan ;
Zethelius, Bjorn ;
Eliasson, Bjorn ;
Gudbjornsdottir, Soffia .
DIABETES OBESITY & METABOLISM, 2016, 18 (10) :990-998
[10]   Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin [J].
Evans, JMM ;
Ogston, SA ;
Emslie-Smith, A ;
Morris, AD .
DIABETOLOGIA, 2006, 49 (05) :930-936